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Transrectal ultrasound (TRUS) guided prostate
needle biopsy is the standard diagnostic proce-
dure for detecting prostate cancer. Since the late
1980s, prostate specific antigen (PSA) has been
used for the screening of prostate cancer. TRUS
guided prostate needle biopsy became one of the
most common procedures in the daily practice of
urologists.1 Although TRUS guided prostate needle
biopsy is generally considered to be a safe and
easy procedure, complications are occasionally
encountered. In previous literature, Berger et al
reported 5957 prostate biopsies performed from
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Background/Purpose: Complications from transrectal ultrasound (TRUS) guided prostate needle biopsy
are occasionally encountered in the daily practice of urologists. We tried to determine the associated risk
factors of patients who suffered from major complications that required hospitalization after TRUS guided
prostate needle biopsies.
Methods: We did a retrospective review of 1875 TRUS guided prostate biopsies performed between
January 2002 and December 2005. We defined major complications as patients with complications that
needed hospitalization. We analyzed the association between biopsy complications and suspected factors,
including age, prostate volume, patient’s underlying disease, selection of prophylactic antibiotics, biopsy
core numbers (6, 12, and 15 cores), and antiplatelet/anticoagulant usage.
Results: There were 124 patients (6.6%) with major complication. These major complications were catego-
rized as acute prostatitis (3.8%), acute urinary retention (2.1%), hematuria (1.9%), rectal bleeding (0.2%),
epididymitis (0.2%), sepsis (0.05%), and vasovagal syncope (0.05%). Patients with larger prostate size were
noted to have higher risk of developing transient acute prostatitis and acute urinary retention after prostate
biopsy. In contrast, age, prophylactic antibiotics (levofloxacin and pipemidic acid), underlying diseases (dia-
betic mellitus, hypertension, hyperlipidemia, cerebrovascular accident, coronary artery disease), increased
biopsy core numbers, and antiplatelet/anticoagulant usage were not associated with major complications
after prostate biopsy.
Conclusion: TRUS guided prostate needle biopsy is a safe diagnostic tool in most elderly males with or
without systemic underlying disease. [J Formos Med Assoc 2007;106(11):929–934]
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1993 to 2002 in Austria, retrospectively. Minor
complications included hematospermia (36.3%),
hematuria (14.5%) and rectal bleeding that per-
sisted for up to 2 days (2.3%).2 Major compli-
cations included fever (0.8%), rectal bleeding
requiring surgical intervention or persisting for
more than 2 days (0.6%) and urinary retention
(0.2%). Djavan et al reviewed previous reports 
of complications after TRUS prostate needle
biopsy. Immediate and delayed complications
were reported, including urinary tract infection
(1.2–11.3%), fever (1.4–4.5%), sepsis (0.1–0.3%),
hematuria (12.5–58.4%), hematospermia (5.1–
45.3%), rectal bleeding (2.1–37.1%), urinary 
retention (0.2–2.6%), and voiding difficulty (6.7–
13.7%).3 Complication rates were variable prob-
ably due to different definitions of complication
by authors. The incidence and mortality rate of
prostate cancer have gradually increased with in-
dustrialization in Taiwan.4 The usage of TRUS
prostate biopsies may progressively increase with
the importance of prostate cancer screening. Thus,
we did a retrospective study of 1875 TRUS guided
prostate needle biopsies from a single institution
in Taiwan and tried to determine the associated
risk factors of patients who suffered from major
complications that needed hospitalization after
TRUS guided prostate needle biopsies.
Methods
We did a retrospective study by reviewing the med-
ical records of 1875 TRUS guided prostate biop-
sies performed in a single institution between
January 2002 and December 2005. The predom-
inant indication for biopsy was an increased PSA
level and/or abnormal digital rectal examination.
Rectal preparation with bisacodyl was performed
6 hours before biopsy. Patients with antiplatelet/
anticoagulation agents were instructed to discon-
tinue aspirin 7 days before biopsy and to discon-
tinue warfarin 3 days before biopsy. Between
January 2002 and December 2004, patients re-
ceived pipemidic acid 500mg twice daily for 3 days
from the day of biopsy. Between January 2005
and December 2005, patients received levoflox-
acin 500 mg single dose on the morning before
biopsy.
Patients’ variables, including age, prostate vol-
ume, prophylactic antibiotics, underlying diseases,
biopsy core numbers, pathologic results, and anti-
platelet (aspirin)/anticoagulant (warfarin) usage
were assessed. We defined major complications
as patients with complications that needed hospi-
talization. These major complications were catego-
rized as fever, hematuria, acute urinary retention,
rectal bleeding, epididymitis, sepsis, and vasovagal
syncope. Results were analyzed with commercial
statistical software and p values were calculated
with χ2 test, t test, ANOVA, and logistic regression.
Statistically significant difference was defined as
p < 0.05.
TRUS examinations were performed with a
real-time ultrasound scanner (B&K 1846 model)
using a 7-MHz transducer. Prostate volume was
calculated from the TRUS image using the formula
volume (mL) = 0.52× length×width×height (cm).
Patients were placed in the left decubitus posi-
tion. Biopsies were done with 18G tru-cut biopsy
needles during longitudinal scanning. The proce-
dure was performed by eight chief residents alter-
natively with attendings’ supervision.
Results
A total of 1875 TRUS guided prostate biopsies
were performed between January 2002 and
December 2005; 1199 patients (63.9%) received
prostate biopsy during admission and 676 patients
(36.1%) received prostate biopsy at the outpatient
clinic. There were 536 (28.58%) patients who
were diagnosed with prostate cancer.
Complications
Of the 1875 TRUS guided prostate needle biopsies,
124 patients (6.6%) were noted to have major
complications that needed further hospitali-
zation. These major complications were 3.8%
acute prostatitis (55 of 1875), 2.1% acute uri-
nary retention (39), 1.9% hematuria (36), 0.2%
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rectal bleeding (4), 0.2% epididymitis (4), 0.05%
sepsis (1), and 0.05% vasovagal syncope (1).
Age
Of the 1875 TRUS guided prostate needle biop-
sies, patients’ age was between 45 and 94 years.
The mean age of patients was 67.3 ± 10.2 years.
In the group of patients with major complica-
tions (C Group), their mean age was 68.0 ± 11.4
years. In the group of patients without major
complications (NC Group), their mean age was
67.2 ± 10.1 years. There was no significant differ-
ence in patient age identified between patients
with (C Group) and without major complications
(NC Group) (p = 0.407).
Volume
The range of prostate volume was from 11.3 
to 176 mL. Mean prostate volume was 44.7 ±
22.3 mL. The mean prostate volume in the C
Group was 52.6 ± 26.0 mL, while it was 44.1 ±
21.9 mL in the NC Group. There was a significant
difference in prostate volume between patients
with (C Group) and without major complica-
tions (NC Group) (p = 0.001). By reviewing like-
lihood ratio statistics and areas under the curve
from logistic regression models to complication
occurrence, prostate volume was analyzed using
indicator variables for each 5 mL, and the cut-
off point with the largest area under the curve
was 45 mL. Patients with a prostate volume
greater than 45 mL (8.1%) were more likely to
suffer from biopsy complications than patients
with prostate volume less than 45 mL (6.0%)
(p < 0.05).
Major complications were further divided into
fever (acute prostatitis), acute urinary retention,
hematuria, rectal bleeding, epididymitis, sepsis,
and vasovagal syncope. There was significant dif-
ference in prostate volume measured between pa-
tients with and without acute prostatitis (p=0.001)
and acute urinary retention (p= 0.019) (Figure).
In contrast, there was no significant difference in
prostate volume measured between patients with/
without hematuria, epididymitis, rectal bleeding,
and others (p > 0.05).
Core numbers of needle biopsies
Of the 1875 TRUS guided prostate needle biop-
sies, 931 patients received the standard sextant
biopsy (6 core), 841 patients received sextant and
lateral biopsy (12 core), and 84 patients received
sextant combined lateral biopsy, and additional
nodule biopsy (15 core). There were 59 patients
with major complications in the 6-core group
(59/931, 6.34%), 58 patients with major compli-
cations in the 12-core group (58/841, 6.9%), and
five patients with major complications in the 
15-core group (6/84, 6.95%). There was no signif-
icant difference in complication rates among the
6-, 12- and 15-core groups (p > 0.05).
Prophylactic antibiotics
Between January 2002 and December 2004, 1373
patients received pipemidic acid 500 mg twice
daily for 3 days from the day of prostate biopsy.
Between January 2005 and December 2005, 502
patients received levofloxacin 500 mg single dose
on the morning before biopsy. There were 96 pa-
tients with major complications in the pipemidic
acid group (96/1373, 7%) and 28 patients with
major complications in the levofloxacin group
(28/502, 5.6%). There was no significant difference
in total complication rate between the pipemidic
acid and levofloxacin groups (p>0.05). The infec-
tion complication rates were 3.27% and 1.99%
in the pipemidic acid and levofloxacin groups,
respectively. There was no significant difference
in infection rate with the different antibiotics
(p > 0.05).
Complications and risk factors of TRUS guided prostate needle biopsy
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Figure. Comparison of complication rate between prostate
volume greater and less than 45 mL.
Antiplatelet medication and anticoagulant
Of the 1875 TRUS guided prostate needle biop-
sies, 180 patients received antiplatelet medication
and anticoagulants: 173 received aspirin and
seven have received warfarin. Aspirin was discon-
tinued 7 days before biopsy. Warfarin was dis-
continued 3 days before biopsy. Complication
rate after prostate biopsy was 8.9% in all patients
who received antiplatelet medication and anti-
coagulant, 10% in the aspirin group, and 0% in
the warfarin group. There was no significant dif-
ference in complication rate after prostate biopsy
between patients with/without aspirin or warfarin
usage with adequate period of discontinuation
(p > 0.05).
Underlying diseases
Of the 1875 TRUS guided prostate needle biop-
sies, there were 130 patients with diabetes melli-
tus (DM), 315 patients with hypertension, 133
patients with hyperlipidemia, 44 patients with
previous cerebrovascular disease (CVA), 213 pa-
tients with coronary artery disease (CAD), and
61 patients with hepatic disease. Complication rate
after prostate biopsy was 6.2% in the DM group,
7.4% in the hypertension group, 9% in the hyper-
lipidemia group, 7.6% in the CVA group, 8% in
the CAD group, and 11.5% in the hepatic disease
group. There was no significant difference in
complication rate after prostate biopsy between
patients with and without these underlying 
diseases (p > 0.05) (Table).
Discussion
In this retrospective study of 1875 cases, with re-
gard to age, prostate volume, prophylactic antibi-
otics, underlying diseases, biopsy core numbers,
and antiplatelet (aspirin)/anticoagulant (warfarin)
usage, we noted that prostate volume was the only
risk factor that was associated with major compli-
cations after TRUS guided prostate needle biopsy.
There was significant difference in prostate vol-
ume measured between patients with (C Group,
52.6±26.0 mL) and without major complications
(NC Group, 44.1±21.9 mL). A prostate volume of
45 mL was identified as the cut-off value that indi-
cated which patients would be more prone to hav-
ing post-biopsy complications. Raaijmakers et al
evaluated 5802 patients who received TRUS pro-
state needle biopsies in the Netherlands.5 They
reported minor complications, including hema-
turia for more than 3 days (22.6%) and hemato-
spermia (50.4%), as well as major complications,
including fever (3.5%) and urinary retention
(0.4%). Their risk factor analysis yielded prostate
volume, transition zone volume/total prostate vol-
ume ratio, and a higher International Prostate
Symptom Score, as predictors of urinary reten-
tion. Our results are compatible with those of their
study. After dividing major complications into
fever (acute prostatitis), hematuria, acute urinary
retention, rectal bleeding, epididymitis and others,
there was a significant difference in prostate vol-
ume measured between patients with and without
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Table. Potential risk factors and complication rates
Risk factor
Complication rate (%)
p
+ −
Diabetes mellitus 6.2 6.6 0.50
Hypertension 7.6 6.5 0.45
Cerebrovascular accident 7.7 6.5 0.16
Coronary artery disease 8.0 6.4 0.38
Hepatic disease 11.1 6.5 0.18
Aspirin 10.0 6.3 0.11
Warfarin 6.6 0 1.00
Biopsy cores 6 12 15
Complication rate (%) 6.34 6.90 6.95 0.23
acute prostatitis (p = 0.001) and acute urinary re-
tention (p=0.019). In contrast, there was no signif-
icant difference in prostate volume measured
between patients with and without hematuria, epi-
didymitis, rectal bleeding and others (p> 0.05).
This information was of little value in clinical deci-
sions, because it is not acceptable to hold prostate
biopsy due to large prostate size. Sech et al have
reported interexaminer differences in prostate
volume measurement with TRUS. However, total
prostate volume reliability was higher for prostate
volume >40 mL.6 Thus, we could inform patients
with larger prostate size in advance that there
might be a higher risk of developing transient
acute prostatitis and acute urinary retention after
prostate biopsy.
In our study, the complication rate did not in-
crease with biopsy core numbers. There was no sig-
nificant difference between protocols with 6, 12
and 15 cores. Berger et al also compared complica-
tion rate of protocols with 6, 10 and 15 biopsy
cores and found no difference.2
There has been debate about antibiotic prophy-
laxis of TRUS prostate needle biopsy.7–12 Different
regimens with different routes, dosage, duration
and different costs are available. Enlund and
Varenhorst stated that antibiotic prophylaxis might
not be necessary.13 They did 415 prostate biopsies
without prophylactic antibiotics. Complication
rate of fever was 2.9%, which did not far exceed
the complication rate of fever in other studies.
Taylor and Bingham recommended oral ciproflox-
acin or norfloxacin with/without metronidazole.7
Griffith et al proposed that a single dose of 500 mg
levofloxacin represented excellent infection pro-
phylaxis of TRUS guided prostate biopsy with
low infection rate because levofloxacin, one of the
new generation of quinolones, is highly effective
against Gram-negative organisms, which are the
most common pathogens responsible for infec-
tion after biopsy.14 We have adopted the simple
and convenient regimen suggested by Griffith et al
since 2005 due to the low infection rate in their
study. In our study, the total complication rate (7%
vs. 5.6%) and infection rate with acute prostatitis
(3.2% vs. 1.99%) showed no significant difference
between 3-day usage of pipemidic acid and a sin-
gle dose of levofloxacin.
The efficacy of decreasing infection rate with
rectal enema has been a topic of debate in the 
literature. Lindert et al conducted a prospective
randomized study, which proposed that enema
before biopsy may decrease bacteremia and bac-
teriuria after prostate biopsy.15 All of the patients
in our study received rectal preparation with bis-
acodyl based on the opinion of Lindert et al.
Thus, there was no control group without enema
in our study.
In consideration of antiplatelet and anticoagu-
lant usage in the elderly, we studied the association
between aspirin/warfarin usage and post-biopsy
complication rate. We noted that if patients were
instructed to discontinue aspirin for 7 days and
coumadin for 3 days before biopsy, then the com-
plication rate would not increase in this group.
There is no previous literature discussing 
comorbidity and complication rate. In our study,
we found that patients with hypertension, DM,
CVA, CAD, and hepatic disease did not have higher
risks of complications after TRUS guided prostate
needle biopsy.
In conclusion, TRUS guided prostate needle
biopsy is a safe diagnostic tool in most elderly
males with and without systemic underlying dis-
ease. The only risk factor associated with prostate
biopsy was large prostate size. Patients with pro-
state volume >45 mL should be informed of the
increased complication rate of having post-biopsy
acute prostatitis and urinary retention. Age, pro-
phylactic antibiotics (levofloxacin and pipemidic
acid), underlying diseases (DM, hypertension,
hyperlipidemia, CVA, CAD), increased biopsy core
numbers, and antiplatelet/anticoagulant usage
were not associated with major complications after
prostate biopsy.
References
1. Fitzsimons NJ, Sun L, Moul JW. Medical technologies for
the diagnosis of prostate cancer. Expert Rev Med Devices
2007;4:227–39.
Complications and risk factors of TRUS guided prostate needle biopsy
J Formos Med Assoc | 2007 • Vol 106 • No 11 933
2. Berger AP, Gozzi C, Steiner H, et al. Complication rate of
transrectal ultrasound guided prostate biopsy: a compari-
son among 3 protocols with 6, 10 and 15 cores. J Urol
2004;171:1478–80.
3. Djavan B, Waldert M, Zlotta A, et al. Safety and morbidity
of first and repeat transrectal ultrasound guided prostate
needle biopsies: results of a prospective European prostate
cancer detection study. J Urol 2001;166:856–60.
4. Chang CK, Yu HJ, Chan KW, Lai MK. Secular trend and
age-period-cohort analysis of prostate cancer mortality in
Taiwan. J Urol 1997;158:1845–8.
5. Raaijmakers R, Kirkels WJ, Roobol MJ, et al. Complication
rates and risk factors of 5802 transrectal ultrasound-guided
sextant biopsies of the prostate within a population-based
screening program. Urology 2002;60:826–30.
6. Sech S, Montoya J, Girman CJ, et al. Interexaminer reliabil-
ity of transrectal ultrasound for estimating prostate volume.
J Urol 2001;166:125–9.
7. Taylor HM, Bingham JB. The use of prophylactic antibiotics
in ultrasound-guided transrectal prostate biopsy. Clin Radiol
1997;52:787–90.
8. Larsson P, Norming U, Tornblom M, Gustafsson O. Anti-
biotic prophylaxis for prostate biopsy: benefits and costs.
Prostate Cancer Prostatic Dis 1999;2:88–90.
9. Puig J, Darnell A, Bermudez P, et al. Transrectal ultrasound-
guided prostate biopsy: is antibiotic prophylaxis necessary?
Eur Radiol 2006;16:939–43.
10. Sabbagh R, McCormack M, Peloquin F, et al. A prospec-
tive randomized trial of 1-day versus 3-day antibiotic pro-
phylaxis for transrectal ultrasound guided prostate biopsy.
Can J Urol 2004;11:2216–9.
11. Tobias-Machado M, Correa TD, De Barros EL, Wroclawski
ER. Antibiotic prophylaxis in prostate biopsy. A comparative
randomized clinical assay between ciprofloxacin, norfloxacin
and chloramphenicol. Int Braz J Urol 2003;29:313–9.
12. Yang L, Hu J, Wei H, et al. Clinical significance of antibiotic
prophylaxis for transrectal prostate biopsy. Zhonghua Wai
Ke Za Zhi 2001;39:940–2. [In Chinese]
13. Enlund AL, Varenhorst E. Morbidity of ultrasound-guided
transrectal core biopsy of the prostate without prophylactic
antibiotic therapy. A prospective study in 415 cases. Br J
Urol 1997;79:777–80.
14. Griffith BC, Morey AF, Li-Khan MM, et al. Single dose levo-
floxacin prophylaxis for prostate biopsy in patients at low
risk. J Urol 2002;168:1021–3.
15. Lindert KA, Kabalin JN, Terris MK. Bacteremia and bac-
teriuria after transrectal ultrasound guided prostate biopsy.
J Urol 2000;164:76–80.
I.N. Chiang, et al
934 J Formos Med Assoc | 2007 • Vol 106 • No 11
